Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The lack of statistically significant reduction in infarct volume, despite a numerical decrease, suggests that DSIPs primary benefit in this model might be more related to functional neurorecovery and neural network plasticity rather than a direct, massive reduction of necrotic tissue [1]
Semaglutide is a GLP-1 receptor agonist that suppresses appetite, delays gastric emptying, and improves glucose-dependent insulin secretion
FOXO4-DRI theoretically has higher selectivity by targeting the FOXO4-p53 interaction that is specifically elevated in senescent cells
Additional measurements of metabolic parameters in one monkey and three rats revealed rapid clearance of DSIP from plasma, with half-lives of 2.9 and 2.0 +/- 0.54 minutes, respectively
US$ 29.93
US$ 20.95
US$ 28.60
